BACKGROUND: Psychiatric symptoms occur frequently in the course of AD, are a frequent contributor to institutionalization, predict cognitive decline and death, and often require treatment with psychotropic medications. Previous studies investigating the association between APOE genotype and psychiatric symptomatology in AD have reported contradictory results. OBJECTIVE: To determine whether APOE genotype predicts incident psychiatric symptomatology in patients with AD. METHODS: Eighty-seven patients with AD at early stages and no psychiatric history were followed semiannually for up to 9.3 years (mean 5.5 years) for development of delusions, illusions, hallucinations, behavioral symptoms, and depression. Cox proportional hazards models were used to examine the relative risk for incident psychiatric symptomatology (outcome) in relation to APOE genotype (predictor). RESULTS: The presence of one epsilon4 allele carried a 2.5-fold risk, whereas the presence of two epsilon4 alleles carried a 5.6-fold risk for development of delusions. The associations remained significant even when age, ethnicity, sex, education, duration of disease, and cognitive and functional performance were controlled for. The presence of two epsilon4 alleles was associated with reduced risk for developing hallucinations in the adjusted analysis only. No significant associations were detected between APOE genotype and the incidence of illusions, behavioral symptoms, or depression. CONCLUSION: The presence of one or more epsilon4 alleles is a significant predictor for the incidence of delusions in the course of AD.
BACKGROUND:Psychiatric symptoms occur frequently in the course of AD, are a frequent contributor to institutionalization, predict cognitive decline and death, and often require treatment with psychotropic medications. Previous studies investigating the association between APOE genotype and psychiatric symptomatology in AD have reported contradictory results. OBJECTIVE: To determine whether APOE genotype predicts incident psychiatric symptomatology in patients with AD. METHODS: Eighty-seven patients with AD at early stages and no psychiatric history were followed semiannually for up to 9.3 years (mean 5.5 years) for development of delusions, illusions, hallucinations, behavioral symptoms, and depression. Cox proportional hazards models were used to examine the relative risk for incident psychiatric symptomatology (outcome) in relation to APOE genotype (predictor). RESULTS: The presence of one epsilon4 allele carried a 2.5-fold risk, whereas the presence of two epsilon4 alleles carried a 5.6-fold risk for development of delusions. The associations remained significant even when age, ethnicity, sex, education, duration of disease, and cognitive and functional performance were controlled for. The presence of two epsilon4 alleles was associated with reduced risk for developing hallucinations in the adjusted analysis only. No significant associations were detected between APOE genotype and the incidence of illusions, behavioral symptoms, or depression. CONCLUSION: The presence of one or more epsilon4 alleles is a significant predictor for the incidence of delusions in the course of AD.
Authors: P P De Deyn; K Rabheru; A Rasmussen; J P Bocksberger; P L Dautzenberg; S Eriksson; B A Lawlor Journal: Neurology Date: 1999-09-22 Impact factor: 9.910
Authors: M Mauricio; R O'Hara; J A Yesavage; L Friedman; H C Kraemer; M Van De Water; G M Murphy Journal: Am J Geriatr Psychiatry Date: 2000 Impact factor: 4.105
Authors: Fumiko Irie; Kamal H Masaki; Helen Petrovitch; Robert D Abbott; G Webster Ross; Dennis R Taaffe; Lenore J Launer; Lon R White Journal: Arch Gen Psychiatry Date: 2008-08
Authors: Nikolaos Scarmeas; Lawrence S Honig; Hyunmi Choi; Julio Cantero; Jason Brandt; Deborah Blacker; Marilyn Albert; Joan C Amatniek; Karen Marder; Karen Bell; W Allen Hauser; Yaakov Stern Journal: Arch Neurol Date: 2009-08
Authors: Ann Kolanowski; Marie Boltz; Elizabeth Galik; Laura N Gitlin; Helen C Kales; Barbara Resnick; Kimberly S Van Haitsma; Amy Knehans; Jane E Sutterlin; Justine S Sefcik; Wen Liu; Darina V Petrovsky; Lauren Massimo; Andrea Gilmore-Bykovskyi; Margaret MacAndrew; Glenna Brewster; Vycki Nalls; Ying-Ling Jao; Naomi Duffort; Danny Scerpella Journal: Nurs Outlook Date: 2017-06-16 Impact factor: 3.250
Authors: A L Pritchard; J Harris; C W Pritchard; J Coates; S Haque; R Holder; P Bentham; C L Lendon Journal: J Neurol Neurosurg Psychiatry Date: 2006-09-15 Impact factor: 10.154
Authors: N Scarmeas; G M Hadjigeorgiou; A Papadimitriou; B Dubois; M Sarazin; J Brandt; M Albert; K Marder; K Bell; L S Honig; D Wegesin; Y Stern Journal: Neurology Date: 2004-09-28 Impact factor: 9.910